{"disease":{"id":"immunotherapy-gastrict-cancer","name":"immunotherapy gastrict cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06706466","title":"Evaluate the Prognostic Significance of Changes in the Systemic Immune-Inflammation Index in Patients with AGC Treated with ICI Therapy.","phase":"","overall_status":"COMPLETED","enrollment_count":410,"lead_sponsor_name":"Chang-Ming Huang, Prof.","has_results":false},{"nct_id":"NCT05699655","title":"Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false},{"nct_id":"NCT05223088","title":"Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}